目的 探讨注射用益气复脉（冻干）对冠心病合并慢性心力衰竭患者的临床疗效。方法 回顾性选取三六三医院2021年1月—2022年1月收治的冠心病合并慢性心力衰竭患者110例为研究对象。根据治疗方案不同分为对照组和试验组，每组各55例。对照组患者采用常规治疗方案，试验组在对照组基础上加用注射用益气复脉（冻干）治疗：注射用益气复脉（冻干）5.2 g加入5%葡萄糖注射液250 mL中静脉滴注，每分钟约40滴，每日1次，疗程14 d。两组均于治疗2周后评估疗效，分别于治疗前后采用多普勒彩色超声诊断仪检测两组患者左室收缩末期内径（LVESD）、左室舒张末期内径（LVEDD）、左室射血分数（LVEF），以及血清末端脑钠肽前体（NT-proBNP）、超敏C-反应蛋白（hs-CRP）水平。结果 试验组临床疗效总有效率为92.73%，显著高于对照组的83.64%，差异有统计学意义（P<0.05）。治疗后两组患者LVEF均较本组治疗前显著提高（P<0.05），LVESD、LVEDD均较本组治疗前显著降低（P<0.05），治疗后与对照组比较，试验组LVEF显著提高（P<0.05），LVEDD显著降低（P<0.05），LVESD差异无统计学意义（P>0.05）。治疗后两组患者血清NT-proBNP、hs-CRP水平均较本组治疗前明显降低（P<0.05），且治疗后试验组与对照组比较，NT-proBNP、hs-CRP水平下降更显著（P<0.05）。结论 在常规治疗基础上加用注射用益气复脉（冻干）治疗冠心病合并慢性心力衰竭患者，能明显改善临床症状及心功能，降低NT-proBNP和hs-CRP，提高临床疗效。

Objective To investigate the clinical effect of Yiqi Fumai Lyophilized Injection on patients with coronary atherosclerotic heart disease (CHD) and chronic heart failure. Methods A total of 110 patients with CHD and chronic heart failure admitted to the 363 Hospital from January 2021 to January 2022 were selected as the study objects. According to different treatment plans, they were divided into control group and experimental group, with 55 cases in each group. Patients in the control group were treated with conventional treatment scheme, while the patients in the experimental group were treated with Yiqi Fumai Lyophilized Injection on the basis of the control group:5.2 g of Yiqi Fumai Lyophilized Injection was added with 250 mL of 5% glucose injection for intravenous drip, about 40 drops per minute, once a day, and the course of treatment was 14 days. The efficacy of the two groups was evaluated after two weeks of treatment. Before and after treatment, the left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF) were detected by Doppler color ultrasound diagnostic apparatus, as well as the level of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) and hypersensitive Creactive protein (hs-CRP) were detected. Results The total effective rate of the experimental group was 92.73%, which was significantly higher than that of the control group (83.64%, P<0.05). After treatment, LVEF of patients in the two groups were significantly increased (P<0.05), LVESD and LVEDD were significantly decreased (P<0.05). Compared with the control group after treatment, LVEF in the experimental group was significantly increased (P<0.05), LVEDD was significantly decreased (P<0.05), and LVESD had no significant difference (P>0.05). After treatment, the levels of NT-proBNP and hs-CRP in the two group were significantly lower than those before treatment (P<0.05). After treatment, the levels of NT-proBNP and hs-CRP in the experimental group were significantly lower than those in the control group (P<0.05). Conclusion On the basis of routine treatment, Yiqi Fumai Lyophilized Injection can significantly improve clinical symptoms and cardiac function, reduce NT-proBNP and hs-CRP, and improve clinical efficacy in patients with CHD and chronic heart failure.

R972